Navigation Links
Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Date:8/19/2007

- Early Antiviral Activity with HCV-796 Supports Follow-up with Standard of

Care Including Evaluation of Sustained Virologic Response (SVR) -

- Company to Host Conference Call at 10:00 AM ET Today -

EXTON, Pa., Aug. 10 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced today the decision made with Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), to discontinue dosing with HCV-796 in combination with pegylated interferon and ribavirin in its current Phase 2 study. All subjects, following consultation with the principal investigators at each site, will have the option of continuing on the combination therapy of pegylated interferon and ribavirin, the standard of care. This decision follows yesterday's review by the joint safety review board of safety data accumulated to date, which show elevated liver enzyme levels in some patients after 8 weeks or more of therapy with HCV-796 with pegylated interferon and ribavirin.

The companies conducted a thorough safety review of liver enzyme levels in all patients. Clinically significant elevations of liver enzymes were observed in approximately eight percent of patients receiving HCV-796, including two patients who experienced serious adverse events leading to withdrawal from active therapy with HCV-796, pegylated interferon and ribavirin. In contrast, elevated liver enzymes were seen in only one percent of patients on standard of care. Elevations of liver enzymes appear to be tran
'/>"/>

SOURCE ViroPharma Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. New Information on the Potential of Plasmin Shared at ISTH Congress
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
5. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
9. New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes
10. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
11. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... --  Gaumard® Scientific Company today announced that ... operating system to support an entire family of ... users. UNI® version 2.27.21.0 adds enhanced functionality including ... well as improvements to laboratory functions, patient charting ... EtCO 2 .  First launched ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... , July 30, 2015 Global ... is expected to reach USD 23.01 million in 2022, ... Inc. Growing base of geriatric population, increasing prevalence of ... rising level of awareness among target customer base are ... over the forecast period. According to estimates published by ...
Breaking Medicine Technology:Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
...  Provenance Biopharmaceuticals Corp. ("Provenance") announced today the closing ... Enterprises, LLC for the continued development of anti-cancer ... class of molecules called immunocytokines that are being ... cancer.  Immunocytokines, combine the immune stimulating features of ...
... 22, 2011   Marken announced today that Steve Roese ... organization, which will support Marken,s continued investment in their ... world.  Marken is now accelerating construction of several new depot ... existing locations in Singapore , Mexico and ...
Cached Medicine Technology:Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement 2Marken Appoints New Head of Global Quality Assurance 2
(Date:7/30/2015)... Mequon, Wisconsin (PRWEB) , ... July 30, 2015 , ... ... rejuvenation. Kybella is a nonsurgical treatment designed specifically for the elimination ... is one of the first locations in the state of Wisconsin to offer this ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Earns National Cancer Institute Designation , The Tisch Cancer Institute (TCI) at the ... Institute (NCI)-designated cancer center. TCI joins an elite group of 69 cancer institutions ...
(Date:7/30/2015)... ... 2015 , ... Author Dr. Raul Llanos seeks to empower readers ... self-help book, “ Consciously Healing our Webs of Health, Wellbeing, Success, and Abundance ” ... take responsibility for ourselves, we can create better realities.” His book illustrates the possibilities ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... fight with its Medicare administrative contractor (MAC) over submitted claims for bariatric surgery ... it a challenge to program integrity, Becky Dennis, a nurse auditor at WellSpan ...
(Date:7/30/2015)... UT (PRWEB) , ... July 30, 2015 , ... When trying to gain weight, many people place a lot of ... amount of calories that need to be consumed. However, another key component to successful weight ... gain weight. To assist with this, CB-1 Weight Gainer gives three tips on when ...
Breaking Medicine News(10 mins):Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 2Health News:Hospital Details Fight for Bariatric Surgery Reimbursement in AIS Newsletter 3Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3
... features of the anthroposophical lifestyle, such as restrictive use ... allergic disease in children// , according to a new ... Steiner developed the anthroposophic lifestyle in which health is ... followers integrate modern medicine with alternative, nature-based treatments. ...
... to be reclassified again, according to campaigners. The UK’s Advisory ... drug //is connected to mental disorders. This may result in ... years. It had been classified as a Class C substance ... the use of the drug has to be conducted, as ...
... Erdogan tried to quell fears of a pandemic by saying ... country // , is now under control. ... monitor it closely," Erdogan newsmen with visiting Japanese Prime Minister ... out of the question," he added. People identified as carriers ...
... Indians (NRI) have been called upon by Oscar Fernandes, ... to take an active part in the AIDS awareness ... the involvement of related agencies and organizations to contribute ... announcement while addressing the Panel Discussion on HIV/AIDS in ...
... winter flu in the UK is reported to be on the decline. ... every 100,000 people. This figure // has been on the decline ... reason for this is reported to be the immunity that the people ... the mutations it goes through every year. ,Most of ...
... Scientists at the University of Bonn in Germany have come up ... that a substance present in sunflowers prevents // the AIDS virus ... this would also apply to the actual disease. ,The ... a new class of AIDS drugs. But this is available in ...
Cached Medicine News:Health News:Anthroposophical Lifestyle Reduces Risk Of Allergic Disease In Children 2Health News:Turkish PM says bird flu under control 2Health News:Sunflowers Could Hold the Key to New Class of AIDS Drugs 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: